Related Experiment Video
Updated: Dec 8, 2025
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for
Anne M Macpherson1, Simon C Barry2, Carmela Ricciardelli1
1Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, University of Adelaide, Adelaide 5000, Australia.
Abstract:
Recent advances in the understanding of immune function and the interactions with tumour cells have led to the development of various cancer immunotherapies and strategies for specific cancer types. However, despite some stunning successes with some malignancies such as melanomas and lung cancer, most patients receive little or no benefit from immunotherapy, which has been attributed to the tumour microenvironment and immune evasion. Although the US Food and Drug Administration have approved immunotherapies for some cancers, to date, only the anti-angiogenic antibody bevacizumab is approved for the treatment of epithelial ovarian cancer. Immunotherapeutic strategies for ovarian cancer are still under development and being tested in numerous clinical trials. A detailed understanding of the interactions between cancer and the immune system is vital for optimisation of immunotherapies either alone or when combined with chemotherapy and other therapies. This article, in two main parts, provides an overview of: (1) components of the normal immune system and current knowledge regarding tumour immunology, biology and their interactions; (2) strategies, and targets, together with challenges and potential innovative approaches for cancer immunotherapy, with attention given to epithelial ovarian cancer.
Insights
Cancer immunotherapy shows promise but faces challenges due to the tumor microenvironment. Understanding immune interactions is key to developing effective treatments, especially for epithelial ovarian cancer.
Area of Science:
- Immunology
- Oncology
- Cancer Biology
Background:
- Cancer immunotherapy has advanced, yielding successes in some cancers but limited benefits in others due to tumor microenvironment and immune evasion.
- While approved for some malignancies, immunotherapy options for epithelial ovarian cancer remain limited, with only bevacizumab currently available.
Purpose of the Study:
- To provide an overview of cancer immunotherapy, focusing on epithelial ovarian cancer.
- To detail the components of the immune system and their interaction with tumors.
- To explore current and innovative strategies, targets, and challenges in cancer immunotherapy.
Main Methods:
- Review of current literature on tumor immunology and cancer immunotherapy.
- Analysis of immune system components and their interplay with tumor biology.
- Examination of existing and emerging immunotherapeutic strategies and targets.
Main Results:
- Most patients do not benefit from current immunotherapies due to tumor microenvironment and immune evasion.
- Epithelial ovarian cancer has limited approved immunotherapies, with ongoing clinical trials.
- A comprehensive understanding of tumor-immune interactions is crucial for optimizing immunotherapy.
Conclusions:
- Further research into tumor immunology and immune interactions is vital for advancing cancer immunotherapy.
- Optimizing immunotherapy, potentially in combination with other treatments, requires a deeper understanding of these complex biological processes.
- Innovative strategies are needed to overcome challenges and improve patient outcomes in epithelial ovarian cancer immunotherapy.
More Related Videos
05:42Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
Published on: January 26, 2024
12:42Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression
Published on: August 28, 2012
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...